These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 24721614

  • 1. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.
    Havens JR, Leukefeld CG, DeVeaugh-Geiss AM, Coplan P, Chilcoat HD.
    Drug Alcohol Depend; 2014 Jun 01; 139():9-17. PubMed ID: 24721614
    [Abstract] [Full Text] [Related]

  • 2. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.
    Severtson SG, Bartelson BB, Davis JM, Muñoz A, Schneider MF, Chilcoat H, Coplan PM, Surratt H, Dart RC.
    J Pain; 2013 Oct 01; 14(10):1122-30. PubMed ID: 23816949
    [Abstract] [Full Text] [Related]

  • 3. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.
    McNaughton EC, Coplan PM, Black RA, Weber SE, Chilcoat HD, Butler SF.
    J Med Internet Res; 2014 May 02; 16(5):e119. PubMed ID: 24800858
    [Abstract] [Full Text] [Related]

  • 4. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.
    Butler SF, Cassidy TA, Chilcoat H, Black RA, Landau C, Budman SH, Coplan PM.
    J Pain; 2013 Apr 02; 14(4):351-8. PubMed ID: 23127293
    [Abstract] [Full Text] [Related]

  • 5. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.
    Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD.
    Pharmacoepidemiol Drug Saf; 2013 Dec 02; 22(12):1274-82. PubMed ID: 24123484
    [Abstract] [Full Text] [Related]

  • 6. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ, Ellis MS.
    JAMA Psychiatry; 2015 May 02; 72(5):424-30. PubMed ID: 25760692
    [Abstract] [Full Text] [Related]

  • 7. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.
    Sellers EM, Perrino PJ, Colucci SV, Harris SC.
    J Psychopharmacol; 2013 Sep 02; 27(9):808-16. PubMed ID: 23784739
    [Abstract] [Full Text] [Related]

  • 8. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.
    Cassidy TA, DasMahapatra P, Black RA, Wieman MS, Butler SF.
    Pain Med; 2014 Mar 02; 15(3):440-51. PubMed ID: 24330279
    [Abstract] [Full Text] [Related]

  • 9. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
    Severtson SG, Ellis MS, Kurtz SP, Rosenblum A, Cicero TJ, Parrino MW, Gilbert MK, Buttram ME, Dasgupta N, BucherBartelson B, Green JL, Dart RC.
    Drug Alcohol Depend; 2016 Nov 01; 168():219-229. PubMed ID: 27716575
    [Abstract] [Full Text] [Related]

  • 10. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
    Michna E, Kirson NY, Shei A, Birnbaum HG, Ben-Joseph R.
    Curr Med Res Opin; 2014 Aug 01; 30(8):1589-98. PubMed ID: 24738694
    [Abstract] [Full Text] [Related]

  • 11. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.
    Sessler NE, Downing JM, Kale H, Chilcoat HD, Baumgartner TF, Coplan PM.
    Pharmacoepidemiol Drug Saf; 2014 Dec 01; 23(12):1238-46. PubMed ID: 24916486
    [Abstract] [Full Text] [Related]

  • 12. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
    Hwang CS, Chang HY, Alexander GC.
    Pharmacoepidemiol Drug Saf; 2015 Feb 01; 24(2):197-204. PubMed ID: 25393216
    [Abstract] [Full Text] [Related]

  • 13. Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation.
    Peacock A, Degenhardt L, Hordern A, Larance B, Cama E, White N, Kihas I, Bruno R.
    Int J Drug Policy; 2015 Dec 01; 26(12):1265-72. PubMed ID: 26123898
    [Abstract] [Full Text] [Related]

  • 14. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.
    Rossiter LF, Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Michna E.
    J Med Econ; 2014 Apr 01; 17(4):279-87. PubMed ID: 24559196
    [Abstract] [Full Text] [Related]

  • 15. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L, Larance B, Bruno R, Lintzeris N, Ali R, Farrell M.
    Addiction; 2015 Feb 01; 110(2):226-37. PubMed ID: 25358480
    [Abstract] [Full Text] [Related]

  • 16. The impact of the abuse-deterrent reformulation of extended-release OxyContin on prescription pain reliever misuse and heroin initiation.
    Wolff C, Dowd WN, Ali MM, McClellan C, Meinhofer A, Glos L, Mutter R, Rosenberg M, Schick A.
    Addict Behav; 2020 Jun 01; 105():106268. PubMed ID: 32036188
    [Abstract] [Full Text] [Related]

  • 17. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
    Cassidy TA, Thorley E, Black RA, DeVeaugh-Geiss A, Butler SF, Coplan P.
    J Opioid Manag; 2017 Jun 01; 13(6):425-440. PubMed ID: 29308589
    [Abstract] [Full Text] [Related]

  • 18. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).
    Chilcoat HD, Coplan PM, Harikrishnan V, Alexander L.
    Drug Alcohol Depend; 2016 Aug 01; 165():221-8. PubMed ID: 27372220
    [Abstract] [Full Text] [Related]

  • 19. A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone.
    Peacock A, Degenhardt L, Larance B, Cama E, Lintzeris N, Ali R, Bruno R.
    Pharmacoepidemiol Drug Saf; 2015 Dec 01; 24(12):1321-33. PubMed ID: 26419615
    [Abstract] [Full Text] [Related]

  • 20. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.
    Cheng HG, Coplan PM.
    Postgrad Med; 2018 Aug 01; 130(6):568-574. PubMed ID: 29978755
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.